Explore the latest news from Khondrion and its team.
December 4, 2015 - FOR IMMEDIATE RELEASE Khondrion reports successful outcome of KH176 Phase 1 Clinical trials NIJMEGEN – Khondrion, the...
Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound...
Khondrion receives Orphan Drug Designation for treatment of MELAS syndrome NIJMEGEN – Khondrion, the Dutch pharmaceutical company focusing on small...
NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial...
Former Kinesis Director Clinical Development Edwin Spaans appointed as Khondrion's Chief Medical Officer. NIJMEGEN –December 15, 2014 ‐ Khondrion,...
Published: 25 November 2014 Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of...
2020 – A Year in Review As a new year approaches, Khondrion’s CEO Jan Smeitink reflects on 2020 and the progress Khondrion has made in its research...
1. Tell us about your role as Chief Early Development Officer at Khondrion. There are a lot of different aspects to my role. I help to steer the...
Estimated to affect more than 400 million people around the world, diabetes is one of the most common chronic disorders, with a range of different...
Mitochondrial diseases are a clinically, biochemically and genetically heterogeneous group of disorders. Signs, symptoms and the organs involved can...
Simple functions such as blinking and breathing are actions that we take for granted. However, for those living with Leigh...
1. Tell us about your career before joining Khondrion.I qualified as a Medical Doctor from the University of Utrecht and worked clinically in the...
